GU Cancers 2019 | Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma

Name: Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma
Uploaded: 2019-03-08T16:42:33Z
Duration: 2 min 2 s
Description: Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, Canada, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, where she discusses the promising response rates in the use of the antibody-drug conjugate sacituzumab govitecan in the treatment of metastatic urothelial carcinoma from the TROPHY U-01 study (NCT03547973).

Jeanny Aragon-Ching • 8 Mar 2019

GU Cancers 2019

Bladder Cancer Genitourinary Cancer Antibodies Sacituzumab govitecan

Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, Canada, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, where she discusses the promising response rates in the use of the antibody-drug conjugate sacituzumab govitecan in the treatment of metastatic urothelial carcinoma from the TROPHY U-01 study (NCT03547973).